@article{d364e8c3f446414e82cc9f72bfc8e111,
title = "Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis",
abstract = "This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associated ocular surface disease, by performing univariate and multivariate logistic regression analyses. A total of 469 patients were included, of which 152/469 (32.4%) developed dupilumab-associated ocular surface disease. Multivariate analysis showed a statistically significant association of the development of dupilumab-associated ocular surface disease with a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at the start of dupilumab (odds ratio 5.16, 95% confidence interval 2.30-11.56, p < 0.001). In conclusion, a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at baseline was associated with the development of dupilumab-associated ocular surface disease in patients with atopic dermatitis.",
keywords = "DAOSD, conjunctivitis, dupilumab, dupilumab-associated ocular surface disease",
author = "Achten, {Roselie E} and {Van Luijk}, Chantal and {Van der Rijst}, Lisa and Daphne Bakker and Lotte Spekhorst and Nicolaas Zuithoff and Marie Schuttelaar and Geertruida Romeijn and Angelique Voorberg and Marijke Kamsteeg and Inge Haeck and {De Graaf}, Marlies and Judith Thijs and {De Boer}, Joke and {De Bruin-Weller}, Marjolein",
note = "Funding Information: The authors thank Andrew Walker for critically reading the manuscript. Patients included in this manuscript participated in the BioDay registry sponsored by Sanofi Genzyme. Conflicts of interest: REA has nothing to disclose. CMvL is a speaker for Sanofi Genzyme. LPvdR has nothing to disclose. DSB is a speaker for Sanofi Genzyme and LEO Pharma. LSS has nothing to disclose. NPAZ has nothing to disclose. MLAS is an advisory board member and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme. GLER has nothing to disclose. Angelique N. Voorberg has nothing to disclose. MK is an advisory board member of LEO Pharma. IMH is an advisory board member, and/or speaker for AbbVie, Eli Lilly, Leo Pharma and Sanofi-Genzyme. MdG is a principal investigator and advisory board member and/or speaker for Sanofi Genzyme and Regene-ron Pharmaceuticals and LEO Pharma, and is an advisory board member for Eli Lilly. JLT is a speaker for Sanofi Genzyme and LEO Pharma. JHdB received research funding from Abbvie; this is outside the submitted work. MSdB-W is a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme. Publisher Copyright: {\textcopyright} 2022, Medical Journals/Acta D-V. All rights reserved.",
year = "2022",
month = mar,
day = "11",
doi = "10.2340/actadv.v102.1128",
language = "English",
volume = "102",
pages = "1--7",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Medical Journals Sweden AB",
}